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Abstract 
Cancer-induced bone pain (CIBP) remains a major challenge in advanced cancer 
patients due to our lack of understanding of its mechanisms. Previous studies have 
demonstrated the vital role of GABAB receptors (GABABRs) in regulating 
nociception and various neuropathic pain models have shown diminished activity of 
GABABRs. However, the role of spinal GABABRs in CIBP remains largely 
unknown. In this study, we investigated the specific cellular mechanisms of 
GABABRs in the development and maintenance of CIBP in rats. Our behavioral 
results show that both acute and chronic intrathecal treatment with baclofen, a 
GABABR agonist, significantly attenuated CIBP-induced mechanical allodynia and 
ambulatory pain. The expression levels of GABABRs were significantly decreased in 
a time-dependent manner and colocalized mostly with neuron and a minority with 
astrocyte and microglia. Chronic treatment with baclofen restored the expression of 
GABABRs and markedly inhibited the activation of cAMP-dependent protein kinase 
(PKA) and the cAMP-response element-binding protein (CREB) signaling pathway.  
Perspective: Our findings provide the first evidence that downregulation of 
GABABRs contribute to the development and maintenance of CIBP and restore 
diminished GABABRs attenuates CIBP-induced pain behaviors at least partially by 
inhibiting the PKA/CREB signaling pathway. Therefore, spinal GABABR may 
become a potential therapeutic target for the management of CIBP. 
Keywords: Cancer-induced bone pain; GABAB receptor; PKA; CREB; Baclofen 
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1. Introduction  
More than one-third patients with metastatic bone disease experience moderate to 
severe pain, which significantly debilitates their quality of life 
39, 41, 56
. Cancer-induced 
bone pain (CIBP) is a complex pain state involving background, spontaneous and 
evoked pain 
21, 35, 54
. Currently, the management of CIBP is limited to the use of 
opioids 
28, 55
. However, high dose of opioids often lead to unwanted side effects 
including addiction, sedation, constipation, pruritus, nausea and vomiting 
6, 9
. 
Although marked advances have been made in recent years, the mechanisms of CIBP 
are far from clear. Therefore, further elucidation of the mechanisms of CIBP is 
warranted to reveal novel therapeutic targets. 
γ-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central 
nervous system (CNS), exerts its action via ionotropic GABAA receptors 
(GABAARs) and metabotropic GABAB receptors (GABABRs) 
4
. GABABRs, 
composed of  GABABR1 and  GABABR2,  are G-protein-coupled receptors (GPCRs) 
that elicit primarily inhibitory effects via the inhibition of presynaptic voltage-gated 
Ca
2+
 channels, activation of postsynaptic K
+
 channels, and inhibition of adenylyl 
cyclase 
5, 30
. In the spinal cord, GABABRs are mainly located on laminae I-III where 
nociceptive primary afferent fibers principally terminate 
13
. Evidence is accumulating 
that GABABRs play a vital role in regulating nociception 
20, 34, 40
. Moreover, studies 
suggeste that impairment of GABABRs contribute to neuropathic pain in various 
models including the spinal nerve ligation (SNL) 
23
, spinal cord injury 
16
 and diabetic 
neuropathy 
3, 26, 44
. However, the role of spinal GABABRs in CIBP remains unknown. 
It has been shown that activation of GABABRs could inhibit adenylyl cyclase, and 
thus reduce the activity of cAMP-dependent protein kinase (PKA) signaling 
11
. The 
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PKA complex consists of two catalytic and two regulatory subunits, which bind 
cAMP and phosphorylated cAMP-response element-binding protein (p-CREB), 
respectively 
53
. Several lines of evidence have demonstrated that upregulation of PKA 
and p-CREB contribute to the development of chronic pain including CIBP 
17, 19, 29, 57
. 
If activation of GABABRs could alleviate CIBP, maybe downregulation of PKA and 
p-CREB is one of its intracellular mechanisms, which needs to be investigated. In the 
present study, using a CIBP model induced by intramedullary injection of Walker 256 
cells into the tibia of rats, we tested the hypothesis that activation of GABABRs could 
alleviate CIBP via inhibiting PKA/CREB signaling pathway.  
2. Material and Methods 
2.1. Animals and ethical statement 
Since female rats are more susceptible to Walker 256 mammary gland carcinoma 
cells, we chose virgin female Sprague-Dawley rats (180-200 g, Tongji Medical 
College, Huazhong University of Science and Technology, Wuhan, PR China) in this 
study. Rats were kept under controlled conditions (24 ± 0.5℃, 12 h alternating light-
dark cycle, with ad libitum access to water and food). All experimental protocols were 
approved by the Animal Care and Use Committee of Huazhong University of Science 
& Technology and were in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals and the guidelines of the International 
Association for the Study of Pain 
58
. All efforts were made to minimize the number of 
animals used and their suffering.  
2.2. Intrathecal catheters and drug administration 
As described previously, the intrathecal catheters were administered 5 days prior to 
the establishment of CIBP models 
22, 37, 49
. In brief, the rats were anesthetized by 
intraperitoneal injection (i.p.) of pentobarbital sodium (50 mg/kg). A PE-10 
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polyethylene catheter was then inserted into the subarachnoid space of the spinal cord 
between L5 and L6 spinous processes. The correct position of the catheter was 
verified by a tail flick response immediately after inserting the catheter and further 
confirmed by an intrathecal injection (i.t.) of 2% lidocaine (10 μL). Animals 
exhibiting motor dysfunction were excluded from the experiments.  
R(+)-Baclofen hydrochloride, a GABAB receptor agonist, was purchased from 
Sigma-Aldrich (USA) and dissolved in saline. 10 μL baclofen (0.1 μg, 0.5 μg or 1 μg) 
or vehicle (saline) was intrathecally injected via the implanted catheter, followed by 
10 μL saline for flushing. The dose of baclofen was based on our preliminary results 
and previous reports 
3, 26
. The drug administration protocol was as follows: for acute 
treatment, baclofen (i.t., 0.1 μg, 0.5 μg or 1 μg /10 μL) or vehicle (10 μL) was 
administered on day 21 following CIBP model establishment; for chronic treatment, 
baclofen (i.t., 0.5 μg/10 μL, once a day) or vehicle (10 μL) was administered from day 
3 to day 14. 
2.3. Preparation of carcinoma cells 
Walker 256 rat mammary gland carcinoma cells (4×10
7
 cells/mL, 1 mL) were 
inoculated into the abdominal cavity of a female Sprague-Dawley rat. After 7 days, 
cells were harvested from the ascitic fluid of the above rat. Cells were diluted to 
achieve a final concentration (4×10
7
 cells/mL) for injection using a hemocytometer. 
The single-cell suspensions were maintained on ice prior to surgery.  
2.4. Bone cancer pain model 
The model of CIBP was established as described previously 
10, 15, 27
. Briefly, rats were 
anesthetized with pentobarbital sodium (50 mg/kg, i.p.). After shaving and 
disinfecting the left leg, a minimal incision was made to expose the proximal tibia. 
Then, the prepared Walker 256 cells (4×10
7
 cells/mL, 10 μL) were slowly injected 
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into the bone cavity using a 10 μL Hamilton syringe. For the sham group, 10 μL D-
Hank’s solution was injected instead. The injection site was closed using bone wax as 
soon as the syringe was removed. Finally, the wound was sutured with 3-0 silk thread.  
2.5. Behavioral tests 
Behavioral tests were performed on day 0, 3, 7, 14 and 21 after surgery between 8:00 
and 12:00 to avoid diurnal variation. Mechanical allodynia was assessed by ipsilateral 
hind paw withdrawal threshold (PWT) to von Frey filament stimulation as described 
previously 
38
. Briefly, animals were placed in individual plastic boxes on a metal 
mesh floor and allowed to acclimatize for 30 min. Von Frey filaments, with ascending 
order of forces (1, 2, 4, 6, 8, 10, and 15 g), were applied for up to 6 s per filament to 
the mid-plantar of the right hind paw. Abrupt paw withdrawal, lickings, and shaking 
were considered as positive responses. Once a positive response was established, the 
paw was re-tested after a 5 min-rest, starting with the next descending von Frey 
filament until no response occurred. The lowest amount of force required to elicit a 
positive response was recorded as the PWT (in grams). Ambulatory pain was assessed 
by ipsilateral limb use during normal ambulation in a plastic observation box as 
described previously 
14
. Limb use during spontaneous ambulation was scored on a 
scale of 0 to 4: 0 = complete lack of limb use, 1 = marked limping, 2 = extent between 
1 and 3, 3 = slight limping, 4 = normal use. All the behavioral tests were performed 
by an investigator who was blinded to the experimental design. 
2.6. Immunohistochemistry 
Under deep anesthesia with pentobarbital sodium (60 mg/kg, i.p.), the rats were 
perfused intracardially with saline followed by 4% ice-cold paraformaldehyde in 0.1 
M phosphate buffer saline (PBS). The L4-L5 spinal segments were removed and post-
fixed in 4% paraformaldehyde for 4 h, and subsequently dehydrated in 30 % sucrose 
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solution overnight at 4℃. The samples were sectioned 30 μm thick in a cryostat 
(CM1900, Leica, Germany) and stored in PBS. 
2.6.1. Single immunostainings 
After washing three times in PBS, the sections were blocked with 5% donkey serum 
and 0.3% Triton X-100 for 1 h at 37°C, and then incubated overnight at 4°C with 
rabbit anti-GABABR1 antibody (1:50; DF4934; Affinity) or rabbit anti-GABABR2 
antibody (1:50; A6594; ABclonal) or rabbit anti-PKAca antibody (1:50; ab26322; 
Abcam) or rabbit anti-phospho-CREB (pSer133) antibody (1:50; MA5-11192; 
Thermo). After washing three times in PBS, the sections were incubated with Alexa 
Fluor 488-labeled donkey anti-rabbit secondary antibody (1:500; A-21206; 
Invitrogen) for 2 h at 37°C and were washed in PBS. Nonspecific staining was 
determined by replacing primary or secondary antibodies with an antibody dilution 
buffer. Sections were rinsed, mounted and cover-slipped with 50% glycerol. Images 
were captured using a fluorescence microscope (DM2500, Leica, Germany). The 
GABABR1/GABABR2/PKA/p-CREB-immunolabeled surface areas were measured 
in laminae I-IV of the spinal cord dorsal horn using Image Pro Plus software. 
Quantification of the immunoreactivity was accomplished by calculating the 
percentages of immunostaining ([positive immunoﬂuorescent surface area]/[total 
measured picture area] × 100). Six rats of each group were used for statistical 
analysis. All the image analyses were performed by an investigator who was blinded 
to the experimental design. 
2.6.2. Double-labeling procedures 
For double immunofluorescence, the sections were incubated with a mixture of two 
primary antibodies followed by a mixture of Alexa 488-conjugated and Alexa 594-
conjugated secondary antibodies (1:500; A-21207; Invitrogen). Specifically, to 
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identify the cell types that expressed GABABR1, GABABR2, PKA, and p-CREB, 
each of the antibodies for these molecules was mixed with mouse anti-neuronal nuclei 
antibody (NeuN; neuronal marker; 1:200; MAB377; Millipore), mouse anti-glial 
fibrillary acidic protein antibody (GFAP, astrocytic marker; 1:300; 3670; Cell 
Signaling Technology), or goat anti-Iba1 antibody (microglial marker; 1:300; ab5076; 
Abcam).  
2.7. Western blotting 
Under deep anesthesia with pentobarbital sodium (60 mg/kg, i.p.), the L4-L5 spinal 
segments were removed and homogenized in RIPA lysis buffer containing 50mM Tris 
(pH 7.4), 150mM NaCl，1% Triton X-100，1% sodium deoxycholate，0.1% 
sodium dodecyl sulfate (SDS), 1mM NaF and 2mM EDTA. Then the homogenates 
were centrifuged at 12000 g for 30 minutes at 4°C. The supernatants were collected 
and the protein concentration was measured using the Bradford method. The samples 
were then heated at 95°C for 10 min in a loading buffer (pH 6.8): 250 mM Tris–HCl, 
200 mM Sucrose, 300 mM DTT, 0.01% Coomassie brilliant blue-G, 8% sodium 
dodecyl sulfate (SDS). Equivalent amounts of proteins (50 μg) were separated using 
10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto 
polyvinylidene fluoride membranes (PVDF; IPVH00010; Millipore). After blocking 
with 5% bovine serum albumin in Tris-buffered saline and Tween 20 (TBST, 0.1%) 
for 2 h at 37°C, the membranes were incubated overnight at 4 °C with rabbit anti-
GABABR1 antibody (1:1000; DF4934; Affinity), rabbit anti-GABABR2 antibody 
(1:500; A6594; ABclonal), rabbit anti-PKAca antibody (1:1000; ab26322; Abcam), 
rabbit anti-phospho-CREB (pSer133) antibody (1:500; MA5-11192; Thermo) and 
mouse anti-glyceraldehyde-3-phosphate dehydrogenase antibody (GAPDH; 1:5000; 
AS1039; Aspen), respectively. The membranes were then washed in TBST and 
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incubated with horseradish peroxidase-conjugated goat-anti-rabbit (1:5000; A21020; 
Abbkine) or goat-anti-mouse secondary antibody (1:5000; A21010; Abbkine) for 2 h 
at 37°C. The bands were finally visualized with SuperLumia ECL Plus HRP Substrate 
Kit (K22030; Abbkine) and then detected by a computerized image analysis system 
(BIO-RAD, ChemiDoc XRS+, USA). The intensity of protein blots was quantified 
using System with image Lab software (Bio-rad Laboratories), normalized to loading 
control GAPDH and expressed as the fold of control. The blot density of control 
groups was set as 1. 
2.8. Statistical analysis 
All data are presented as mean ± SEM and analyzed using the GraphPad Prism 
version 5.01 for Windows (Graph Pad Software, San Diego, CA, USA). One-way 
analysis of variance (ANOVA) followed by Bonferroni post hoc test was used for 
Western blot and immunochemistry data. Two-way ANOVA with repeated measures, 
followed by Bonferroni post hoc test was used for PWT and limb use scores. P < 0.05 
was considered statistically significant. 
3. Results 
3.1. Role of spinal GABABRs in CIBP-related behaviors 
No significant differences in pain-related behaviors were observed among all groups 
at baseline. The ipsilateral PWT of CIBP rats were significantly decreased from day 7 
after tumor cell implantation (TCI) to the last observation on day 21 (Figure 1A). 
Similarly, the ipsilateral limb use scores of CIBP rats were clearly decreased over the 
same time frame (Figure 1B). These results indicate that CIBP rats developed 
mechanical allodynia and ambulatory pain. 
To investigate the role of spinal GABABRs in CIBP rats, we intrathecally injected 
baclofen, a GABABR agonist, into sham and CIBP rats. We first tested the analgesic 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
effect of a single dose of baclofen on day 21 following TCI (i.t., 0.1 μg, 0.5 μg or 1 μg 
/10 μL). The behavioral tests were conducted at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3 h after 
baclofen injection. Compared with that of the vehicle group, intrathecal injection of 
0.1 μg baclofen had no significant influence on PWT and limb use scores. However, 
baclofen (i.t., 0.5 μg or 1 μg/10 μL) treatment notably reversed the CIBP-related 
behaviors, beginning at 0.25 h, peaking at 0.5 h and lasting for at least 2 h (Figure 1C 
and D). Moreover, in terms of PWT and limb use scores, significant differences were 
found between these two groups (0.5 μg vs. 1 μg). These results indicate that the 
antinociceptive effects of baclofen are dose-dependent. For chronic treatment, 
baclofen (i.t., 0.5 μg/10 μL, once a day) or vehicle (10 μL) was administered for 12 
days (from day 3 following TCI to day 14), and the behavioral tests were conducted 
before baclofen injection at day 0, 3, 7, 14 and 21. The results showed that both 
mechanical allodynia and ambulatory pain were alleviated considerably in CIBP rats 
treated with baclofen rather than vehicle (Figure 1E and F). To examine whether 
baclofen affect the pain threshold of naïve rats, we intrathecal injection of baclofen 
(0.1 μg, 0.5 μg or 1 μg /10 μL) into naïve rats. The behavioral tests were conducted at 
0, 0.5, 1, 2 h after baclofen injection. The results showed that intrathecal injection of 
baclofen had no significant influence on PWT and limb use scores compared with 
vehicle group (Figure 1G and H). 
Taken together, these results demonstrate that activation of GABABRs attenuates the 
development and maintenance of mechanical allodynia and ambulatory pain 
following TCI, which indicates an important role of GABABRs in CIBP.  
3.2. Expression and cellular localization of spinal GABABRs in CIBP rats 
To investigate the expression and cellular localization of GABABs in the spinal cord 
of CIBP rats, we performed western blot analysis and immunohistochemistry. As 
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shown in Figures 2A-B and 3A-B, the expression of GABABR1 and GABABR2 
protein were significantly and time dependently decreased in CIBP rats, beginning at 
day 7 after TCI and remained at low levels until day 21, the last test day. In contrast, 
GABABR1 and GABABR2 proteins were at a higher level in the spinal cord of sham 
rats. Moreover, our immunohistochemistry data also showed that the expression of 
GABABR1 and GABABR2 were evidently reduced in the ipsilateral spinal cord of 
CIBP rats compared with sham rats (Figures 2C-E and 3C-E). We further conducted 
double immunofluorescence staining of GABABR1 or GABABR2 with NeuN (a 
neuronal marker), GFAP (an astrocytic marker), or Iba-1 (a microglial marker). As 
illustrated in Figures 2F-N and 3F-N, GABABR1 and GABABR2 were 
predominantly colocalized with NeuN, and a minority with GFAP and Iba-1 in the 
superficial spinal cord of CIBP rats. These results demonstrate that spinal GABABRs 
are downregulated after TCI, and expressed mostly in neurons and a minority in 
astrocyte and microglia. 
3.3. Chronic treatment with baclofen restored the expression of GABABRs. 
To investigate whether baclofen exerts its analgesic effect by restoring the diminished 
expression of GABABRs, we chronically treated CIBP rats with baclofen (i.t., 0.5 
μg/10 μL) once a day from day 3 to day 14 following TCI. Three hours after the final 
administration, spinal samples were collected to detect the expressions of GABABR1 
and GABABR2 using western blot and immunohistochemistry. As shown in Figure 
4A-B, the protein expression of GABABRs were significantly upregulated after 
baclofen treatment. Consistent with the western blot data, our immunohistochemistry 
also showed increased immunoreactivity of GABABRs in the superficial dorsal horn 
of spinal cord (Figure 4C-L). These results suggested that chronic treatment with 
baclofen could restore the expression of GABABRs. 
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3.4. Involvement of spinal PKA/CREB signaling pathway in the analgesic effect 
of baclofen 
The PKA/CREB signaling pathway has been shown to participate in the development 
of chronic pain including CIBP. We consistently found that the expression of spinal 
PKA and p-CREB were significantly increased in a time-dependent manner, 
beginning at day 3 after TCI and remained at high levels until day 21, whereas PKA 
and p-CREB were at lower levels in the spinal cord of sham rats (Figures 5A-B and 
6A-B). Moreover, our immunohistochemistry data also showed that the expression of 
PKA and p-CREB was significantly increased in the ipsilateral spinal cord of CIBP 
rats compared with sham rats (Figures 5C-E and 6C-E). However, the cellular 
localization of PKA and p-CREB in the spinal cord under CIBP condition remains 
unknown. Our double immunofluorescence staining showed that PKA was 
colocalized with NeuN, GFAP and Iba-1 and (Figures 5F-N), whereas p-CREB was 
strongly colocalized with NeuN (Figures 6F-N). These results confirm the activation 
of PKA/CREB signaling pathway in the CIBP condition. 
To further examine the involvement of spinal PKA/CREB signaling pathway in the 
analgesic effect of baclofen, we intrathecally injected baclofen (0.5 μg/10 μL) or 
vehicle (10 μL) into CIBP rats or sham rats daily for 12 consecutive days (from day 3 
following TCI to day 14). Three hours after the final administration, spinal samples 
were collected to detect the expressions of PKA and p-CREB using western blot and 
immunohistochemistry. Our results showed that the upregulated protein levels of 
PKA and p-CREB were considerably attenuated by repeated intrathecal injection of 
baclofen (Figures 7A-B). Additionally, our immunofluorescence results showed that 
CIBP-induced activation of PKA and p-CREB was markedly suppressed by baclofen 
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treatment (Figures 7C-L). These results indicate that restored expression of 
GABABRs could suppress the activation of PKA/CREB signaling pathway. 
Collectively, these data suggest that activation of GABABRs alleviates CIBP at least 
partly by inhibiting spinal PKA/CREB signaling pathway.  
4. Discussion 
The current study demonstrated that (1) activation of GABABRs via intrathecal 
administration of baclofen, a GABABR agonist, significantly attenuated CIBP-
induced mechanical allodynia and ambulatory pain in a dose-dependent manner, (2) 
inoculation of Walker 256 mammary gland carcinoma cells into a rat tibia induced 
downregulation of GABABRs in the spinal cord in a time-dependent manner, (3) 
spinal GABABRs were mostly expressed in neurons and a minority in astrocytes and 
microglia, (4) chronic treatment with baclofen restored the expression of GABABRs 
and significantly inhibited the activation of PKA/CREB signaling pathway in CIBP 
rats. Taken together, these results provide the first evidence that activation of spinal 
GABABRs mitigates CIBP at least partially by inhibiting the PKA/CREB signaling 
pathway. 
Despite advanced progressed has been made in the last decades for the management 
of chronic pain
1, 24, 43, 47
, its mechanisms remains far from clear. It has long been 
suggested that diminished inhibitory neurotransmission plays a pivotal role in chronic 
pain states 
46, 50
. As the main inhibitory neurotransmitter in the CNS, GABA exerts its 
effect via ionotropic GABAARs and metabotropic GABABRs 
7
. Spinal GABABRs 
are abundantly expressed in primary afferent fibers and interneurons on laminae I-III 
48
. Genetic deletion of GABABR1 or GABABR2 produces prominent hyperalgesia 
12, 
36
. Previously, impairment of GABABRs has been demonstrated to participate in the 
development of neuropathic pain induced by SNL 
23
, spinal cord injury 
16
 and diabetic 
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neuropathy 
3, 26, 44
. Moreover, activation of GABABRs by intrathecal injection of 
baclofen produces analgesic effects 
2, 42, 51
. In our study, we provided consistent 
results showing that GABABRs were significantly decreased in the ipsilateral spinal 
cord dorsal horn after TCI (Figures 2A-E and 3A-E). Furthermore, the decreased 
expression of GABABRs matches the time frame that coincides with the development 
of mechanical allodynia and ambulatory pain. Notably, both acute and chronic 
treatment with baclofen markedly alleviated the CIBP-induced mechanical allodynia 
and ambulatory pain (Figures 1C-F). These findings indicate that downregulation of 
GABABRs may be important contributors to diminished GABAergic inhibition under 
CIBP condition. More importantly, repeated intrathecal administration of baclofen 
upregulated the protein expression (Figure 3A-B) and immunoreactivity of 
GABABRs (Figure 3C-L), indicating restored expression of GABABRs after baclofen 
treatment. However, it is worth mentioning that several studies reported that loss of 
GABAergic neurons is not necessary for the development of neuropathic pain 
31-33
. 
These inconsistent results might be due to the difference in animal model, time of 
behavioral tests and detection methods. 
PKA has been demonstrated to play a vital role in the processing of nociception at 
both peripheral and central levels 
8, 53
. Moreover, electrophysiological results also 
illustrate that PKA is involved in modulating neuronal excitability in response to 
noxious stimuli 
19, 52
. When PKA is activated, its catalytic subunit can phosphorylate 
CREB in the spinal cord, which contributes to the prolonged synaptic plasticity 
strengthened during central sensitization 
25, 45
. Previous studies have established that 
activation of PKA/CREB signaling pathway is involved in various types of chronic 
pain including CIBP 
17, 29
, and intrathecal treatment with H-89, a PKA inhibitor, 
significantly attenuates CIBP-related behaviors 
18
. It is also shown that GABABR-
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mediated inhibition of adenylyl cyclase reduces PKA activity, thereby influencing the 
regulation of gene expression 
7
. Therefore, we determined whether inhibiting 
PKA/CREB signaling pathway is one of the mechanisms underlying the analgesic 
effect of the GABABR agonist. Consistent with previous researches, we found 
upregulated expression of PKA and p-CREB in the ipsilateral spinal cord of CIBP 
rats, whereas their expression in sham rats was at lower levels (Figures 5A-E and 6A-
E). Furthermore, we performed double immunofluorescence to examine their cellular 
localization. We provided the first evidence that PKA was colocalized with neurons, 
astrocytes and microglia, whereas p-CREB was strongly colocalized with neurons 
under the CIBP condition (Figures 4F-N and 5F-N). In addition, CIBP rats that 
received chronic treatment with baclofen showed decreased expression of PKA and p-
CREB in the ipsilateral spinal cord dorsal horn (Figure 7A-L). These results indicate 
that inhibition of PKA/CREB signaling pathway may contribute to the analgesic 
effect of the GABABR agonist. 
In summary, the present study suggests that downregulation of GABABRs in the 
spinal cord contributes to the initiation and development of CIBP, and restores 
diminished GABABRs attenuates CIBP-induced mechanical allodynia and 
ambulatory pain at least partially by inhibiting the PKA/CREB signaling pathway. 
Therefore, spinal GABABR may become a potential therapeutic target for the 
management of CIBP. 
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Fig. 1. Activation of GABAB receptors (GABABRs) alleviated cancer-induced 
bone pain (CIBP)-related behaviors. (A, B) The ipsilateral paw withdrawal 
thresholds (PWT) and limb use scores were significantly decreased from day 7 after 
tumor cell implantation (TCI) to the last observation on day 21 (***P < 0.001 
compared with the naive group, n = 6 in each group). (C, D) A single dose of baclofen 
(i.t., 0.5 μg and 1 μg, but not 0.1 μg, on day 21) significantly reversed the CIBP-
induced mechanical allodynia and ambulatory pain (*P < 0.05, **P < 0.01, ***P < 
0.001 compared with the vehicle group, #P < 0.05, ##P < 0.01 compared with the 
group treated with 0.5 μg baclofen, n = 6 in each group). The behavioral tests were 
conducted at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3 h after baclofen injection. (E, F) For chronic 
treatment, baclofen (i.t., 0.5 μg/10 μL, once a day) or vehicle (10 μL) was 
administered for 12 days (from day 3 following TCI to day 14). The behavioral tests 
were conducted before baclofen injection at day 0, 3, 7, 14 and 21 after surgery. The 
development of ipsilateral mechanical allodynia and ambulatory pain of CIBP rats 
were significantly delayed and attenuated by baclofen (**P < 0.01, ***P < 0.001 
compared with the sham+vehicle group. #P < 0.05, ##P < 0.01, ###P < 0.001 
compared with the CIBP+vehicle group. n = 6 in each group). (G, H) Intrathecal 
injection of baclofen (0.1 μg, 0.5 μg or 1 μg /10 μL) into naïve rats had no significant 
influence on PWT and limb use scores compared with vehicle group (n = 3 in each 
group). The behavioral tests were conducted at 0, 0.5, 1, 2 h after baclofen injection. 
Fig. 2. Expression and cellular localization of GABAB receptor 1 (GABABR1) in 
spinal cord dorsal horn of cancer-induced bone pain (CIBP) rats. (A, B) Western 
blot analysis showed the time course of GABABR1 expression in sham and CIBP rats 
(***P < 0.001 compared with the sham group. n = 6 in each group). The fold change 
for the density of GABABR1 was normalized to GAPDH for each sample 
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respectively. The fold change of GABABR1 in the sham group was set at 1 for 
quantification. (C-E) Immunohistochemistry data showed that GABABR1 was 
downregulated in the ipsilateral spinal cord dorsal horn at day 21 after tumor cell 
implantation (TCI) (n = 4 in each group). (F-N) Representative photomicrographs of 
GABABR1 (green) double fluorescence labeling with NeuN (red) for neurons, GFAP 
(red) for astrocytes and Iba1 (red) for microglia in the ipsilateral spinal cord at day 21 
after TCI. Photomicrographs were taken from ipsilateral spinal cord dorsal horns 
(laminae I-II; as indicated in C) of CIBP rats (n = 4 in each group). The results 
showed that GABABR1 was co-expressed mostly with neurons (yellow) and a 
minority with astrocytes (yellow) and microglia (yellow).  
Fig. 3. Expression and cellular localization of GABAB receptor 2 (GABABR2) in 
spinal cord dorsal horn of cancer-induced bone pain (CIBP) rats. (A, B) Western 
blot analysis showed the time course of GABABR2 expression in sham and CIBP rats 
(**P < 0.05, ***P < 0.001 compared with the sham group, n = 6 in each group). The 
fold change for the density of GABABR2 was normalized to GAPDH for each sample 
respectively. The fold change of GABABR2 in the sham group was set at 1 for 
quantification. (C-E) Immunohistochemistry data showed that GABABR2 was 
downregulated in the ipsilateral spinal cord dorsal horn at day 21 after tumor cell 
implantation (TCI) (n = 4 in each group). (F-N) Representative photomicrographs of 
GABABR2 (green) double fluorescence labeling with NeuN (red) for neurons, GFAP 
(red) for astrocytes and Iba1 (red) for microglia in the ipsilateral spinal cord at day 21 
after TCI. Photomicrographs were taken from ipsilateral spinal cord dorsal horns 
(laminae I-II; as indicated in C) of CIBP rats (n = 4 in each group). The results 
showed that GABABR2 was co-expressed mostly with neurons (yellow) and a 
minority with astrocytes (yellow) and microglia (yellow).  
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Fig. 4. Repeated intrathecal administration of baclofen reversed tumor cell 
implantation (TCI)-induced downregulation of GABABRs in the spinal cord. (A, 
B) Western blot and data summary showed that baclofen restored the protein 
expression of GABABR1 and GABABR2 (**P < 0.01, ***P < 0.001 compared with 
the sham+vehicle group. #P < 0.05 compared with the CIBP+vehicle group. n = 6 in 
each group). Baclofen (i.t., 0.5 μg/10 μL) or vehicle (10 μL) was administered once a 
day from day 3 following tumor cell implantation (TCI) to day 14. Tissues were 
collected three hours after the last spinal injection. (C-J) Representative 
photomicrographs showed that baclofen reversed TCI-induced downregulation of 
GABABRs in the spinal cord. Baclofen (i.t., 0.5 μg/10 μL) or vehicle (10 μL) was 
administered once a day from day 3 following tumor cell implantation (TCI) to day 
14. Tissues were collected three hours after the last spinal injection. (K, L) 
GABABRs-immunolabeled surface area were quantified from the spinal dorsal horn 
(laminae I-IV; as indicated in C) using Image Pro Plus software. Quantification of 
GABABRs immunoreactivity was accomplished by calculating the percentages of 
immunostaining ([positive immunoﬂuorescent surface area]/[total measured picture 
area] × 100). Six rats of each group were used for statistical analysis (**P < 0.01, 
***P < 0.001 compared with the sham+vehicle group. #P < 0.05 compared with the 
CIBP+vehicle group. n = 6 in each group). 
Fig. 5. Expression and cellular localization of cAMP-dependent protein kinase 
(PKA) in spinal cord dorsal horn of cancer-induced bone pain (CIBP) rats. (A, 
B) Western blot analysis showed the time course of PKA expression in CIBP rats 
(***P < 0.001 compared with the sham group, n = 6 in each group). The fold change 
for the density of PKA was normalized to GAPDH for each sample respectively. The 
fold change of PKA in the sham group was set at 1 for quantification. (C-E) 
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Immunohistochemistry data showed that PKA was upregulated in the ipsilateral spinal 
cord dorsal horn at day 21 after tumor cell implantation (TCI) (n = 4 in each group). 
(F-N) Representative photomicrographs of PKA (green) double fluorescence labeling 
with NeuN (red) for neurons, GFAP (red) for astrocytes and Iba1 (red) for microglia 
in the ipsilateral spinal cord at day 21 after TCI. Photomicrographs were taken from 
ipsilateral spinal cord dorsal horns (laminae I-II; as indicated in E) of CIBP rats (n = 4 
in each group). The results showed that PKA was colocalized mostly with astrocytes 
(yellow) and microglia (yellow) and a minority with neurons (yellow). 
Fig. 6. Expression and cellular localization of phosphorylated cAMP-response 
element-binding protein (p-CREB) in spinal cord dorsal horn of cancer-induced 
bone pain (CIBP) rats. (A, B) Western blot analysis showed the time course of p-
CREB expression in CIBP rats (***P < 0.001 compared with the sham group, n = 6 in 
each group). The fold change for the density of p-CREB was normalized to GAPDH 
for each sample respectively. The fold change of p-CREB in the sham group was set 
at 1 for quantification. (C-E) Immunohistochemistry data showed that p-CREB as 
upregulated in the ipsilateral spinal cord dorsal horn at day 21 after tumor cell 
implantation (TCI) (n = 4 in each group). (F-N) Representative photomicrographs of 
p-CREB (green) double fluorescence labeling with NeuN (red) for neurons, GFAP 
(red) for astrocytes and Iba1 (red) for microglia in the ipsilateral spinal cord at day 21 
after TCI. Photomicrographs were taken from ipsilateral spinal cord dorsal horns 
(laminae I-II; as indicated in E) of CIBP rats (n = 4 in each group). The results 
showed that p-CREB was colocalized mostly with neurons (yellow) and a minority 
with astrocytes (yellow) and microglia (yellow). 
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Fig. 7. Repeated intrathecal administration of baclofen reversed tumor cell 
implantation (TCI)-induced upregulation of PKA and p-CREB in the spinal 
cord.  
(A, B) Western blot and data summary showed inhibitory effect of baclofen on CIBP-
induced increased expression of PKA and p-CREB protein (*P < 0.05, ***P < 0.001 
compared with the sham+vehicle group. ###P < 0.001 compared with the 
CIBP+vehicle group. n = 6 in each group). Baclofen (i.t., 0.5 μg/10 μL) or vehicle (10 
μL) was administered once a day from day 3 following tumor cell implantation (TCI) 
to day 14. Tissues were collected three hours after the last spinal injection.  (C-J) 
Representative photomicrographs showed that baclofen inhibited TCI-induced 
upregulation of PKA and p-CREB in the spinal cord. Baclofen (i.t., 0.5 μg/10 μL) or 
vehicle (10 μL) was administered once a day from day 3 following tumor cell 
implantation (TCI) to day 14. Tissues were collected three hours after the last spinal 
injection. (K, L) PKA/p-CREB-immunolabeled surface area were quantified from the 
spinal dorsal horn (laminae I-IV; as indicated in C) using Image Pro Plus software. 
Quantification of PKA/p-CREB immunoreactivity was accomplished by calculating 
the percentages of immunostaining ([positive immunoﬂuorescent surface area]/[total 
measured picture area] × 100). Six rats of each group were used for statistical analysis 
(***P < 0.001 compared with the sham+vehicle group. ##P < 0.01 compared with the 
CIBP+vehicle group. n = 6 in each group). 
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Highlights 
 
1. The expression levels of GABABRs are significantly decreased in CIBP rats. 
2. Restore diminished GABABRs attenuates CIBP-induced pain behaviors. 
3. Inhibition the PKA/CREB signaling contributes to the analgesic effect of baclofen. 
